Global Corona Virus Vaccine Market, by Vaccine Type (Inactivated Virus, Protein Subunit, Non-replicating Viral Vector, Repurposed Vaccines, RNA Vaccine, DNA Vaccine, and Genetic Vaccines), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 14.5 billion in 2021, and is expected to exhibit a CAGR of 30.9% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Initiatives taken by the U.S. government to ensure the rapid production and distribution of COVID-19 vaccine is expected to boost growth of the global corona virus vaccine market. The table below provides the action taken by the U.S. government to support the Operation Warp Speed (OWP), a national program to accelerate the development, production, and distribution of COVID-19 vaccines.
|Month||Actions To Support OWP|
|March||The United States Department of Health & Human Services (HHS) announced US$ 456 million in funds for Johnson & Johnson's (Janssen) candidate vaccine.||-|
|April||HHS funded nearly US$ 483 million in support for Moderna's candidate vaccine||-|
|May||HHS provided around US$ 1.2 billion in support for AstraZeneca's candidate vaccine||Department of Defense (DoD) and HHS entered into a US$ 138 million contract with ApiJect for over 100 million prefilled syringes for distribution across the U.S. by year-end 2020|
|June||HHS announced a task order with Emergent BioSolutions for the advancement of domestic manufacturing capabilities and capacity for potential COVID-19 vaccine & therapeutics.||HHS and DoD announced a joint effort to expand the manufacturing capacity for vials that may be needed for vaccines and treatments|
HHS funded US$ 1.6 billion in funds to support the large-scale manufacturing of Novavax's vaccine candidate.
|HHS announced a collaboration with Texas A&M University and FUJIFILM for the advancement of domestic manufacturing capabilities and capacity for potential COVID-19 vaccine using another BARDA-supported Center for Innovation in Advanced Department and Manufacturing|
|August||HHS announced a fund of approximately US$ 1 billion to support the large-scale manufacturing and delivery of Johnson & Johnson's (Janssen) investigational vaccine candidate.||HHS & DoD announced that McKesson Corporation will be central distributor of future COVID-19 vaccines and related supplies|
|September||HHS and DoD released two documents outlining detailed strategy to deliver safe and effective COVID-19 vaccine doses in the U.S.|
|October||HHS entered into an agreement with Cytiva for the expansion of the company’s manufacturing capacity for products that are essential in producing COVID-19 vaccines||The agreements with CVS and Walgreens to provide and administer COVID-19 vaccines to residents of long-term care facilities (LTCF) in the U.S.|
|November||HHS and DoD announced partnerships with large chain pharmacies and networks, covering around 60% of pharmacies throughout the 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands.|
Browse 27 Market Data Tables and 26 Figures spread through 201 Pages and in-depth TOC on “Corona Virus Vaccine Market”- Global Forecast to 2027, by Phase of Trial (Phase 1, Phase 2, Phase 3, and Phase 4), by Vaccine Type (Inactivated Virus, Protein Subunit, Non-replicating Viral Vector, Repurposed Vaccines, RNA Vaccine, DNA Vaccine, and Genetic Vaccines), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in the global corona virus vaccine market, click the link below:
Key Takeaways of the Global Corona Virus Vaccine Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.